Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride temporarily lowers male rat fertility without affecting libido.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This review discusses the effectiveness and tolerability of alpha1-adrenoceptor antagonists for managing lower urinary tract symptoms in benign prostatic hyperplasia, reporting no new clinical results.

The authors concluded that preoperative treatment with finasteride for a month effectively reduced perioperative bleeding and shortened hospital stays in patients undergoing transurethral resection of the prostate.

This study found that supraphysiological doses of testosterone alter endothelial relaxation pathways in hypertensive rats, with varied contributions from nitric oxide, prostanoids, and endothelium-derived hyperpolarizing factors, influenced by estrogen and dihydrotestosterone levels.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.

This study found that finasteride at a low dose of 0.1 mg/kg significantly reduced prostate size in male dogs with benign prostatic hyperplasia without causing toxic side effects.

This review discusses the impact of COVID-19 on urological treatment approaches, including the heightened severity of LUTS in men with urological issues and emphasizes the importance of adhering to treatment protocols.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study developed a rapid and sensitive HPLC method for measuring finasteride in bulk and tablet forms, showing high precision and accuracy compared to the official method.

This study found that in rats, combined treatment with finasteride and doxazosin altered epithelial cell behavior and matrix metalloproteinases activity, suggesting effects possibly mediated by TGF-β1 and androgen pathways.

This study found that Origanum vulgare extract improved testicular structure and function in mice against finasteride-induced damage by enhancing antioxidant defense and modulating gene expression related to apoptosis.

This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.

In this study, men with persistent sexual dysfunction after stopping finasteride showed significant vascular, neurologic, and hormonal abnormalities, with severe erectile dysfunction being common.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

In this study, oral finasteride treatment for four weeks reduced the weight of the corpus cavernosum in rats but did not significantly affect erectile function.

This study reported that finasteride 1 mg significantly improved hair growth in men aged 41 to 60 with predominantly vertex male pattern hair loss over 24 months compared to placebo.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.

In this study, Tolterodine Tartrate significantly improved symptoms of overactive bladder and showed fewer adverse reactions compared to the control group treatment.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.

In this study, finasteride 1 mg demonstrated sustained efficacy over 10 years for men with androgenetic alopecia, especially in those over 30 or with higher AGA grades, with minimal side effects reported.